Progyny (NASDAQ:PGNY – Get Rating) issued its quarterly earnings data on Thursday. The company reported $0.09 EPS for the quarter, topping analysts' consensus estimates of $0.05 by $0.04, Briefing.com reports. Progyny had a net margin of 7.39% and a return on equity of 18.11%. The firm had revenue of $195.00 million for the quarter, compared to analyst estimates of $190.51 million. During the same quarter in the previous year, the business posted $0.19 EPS. The firm's revenue was up 51.5% compared to the same quarter last year.
Progyny Price Performance
Shares of PGNY stock opened at $41.15 on Friday. Progyny has a 12 month low of $25.67 and a 12 month high of $68.32. The firm has a market capitalization of $3.78 billion, a P/E ratio of 89.46, a P/E/G ratio of 21.71 and a beta of 1.85. The company's fifty day moving average price is $30.23 and its two-hundred day moving average price is $37.32.
Get Progyny alerts:Insiders Place Their Bets
In other Progyny news, Chairman David J. Schlanger sold 1,452 shares of the business's stock in a transaction on Monday, June 27th. The shares were sold at an average price of $31.21, for a total value of $45,316.92. Following the transaction, the chairman now owns 82,548 shares in the company, valued at approximately $2,576,323.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Chairman David J. Schlanger sold 1,452 shares of the company's stock in a transaction dated Monday, June 27th. The shares were sold at an average price of $31.21, for a total value of $45,316.92. Following the sale, the chairman now owns 82,548 shares in the company, valued at approximately $2,576,323.08. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Norman Payson sold 6,618 shares of the company's stock in a transaction dated Wednesday, May 11th. The shares were sold at an average price of $33.45, for a total transaction of $221,372.10. Following the completion of the sale, the director now owns 490,828 shares in the company, valued at approximately $16,418,196.60. The disclosure for this sale can be found here. Insiders have sold 41,240 shares of company stock worth $1,291,601 in the last quarter. 14.00% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Progyny
Institutional investors have recently modified their holdings of the stock. Vontobel Holding Ltd. bought a new stake in shares of Progyny during the 1st quarter valued at about $1,969,000. Yousif Capital Management LLC grew its position in shares of Progyny by 1.1% during the 1st quarter. Yousif Capital Management LLC now owns 37,264 shares of the company's stock valued at $1,915,000 after buying an additional 392 shares during the last quarter. Eaton Vance Management grew its position in shares of Progyny by 99.8% during the 1st quarter. Eaton Vance Management now owns 32,071 shares of the company's stock valued at $1,649,000 after buying an additional 16,018 shares during the last quarter. Natixis Advisors L.P. grew its position in shares of Progyny by 47.3% during the 1st quarter. Natixis Advisors L.P. now owns 29,595 shares of the company's stock valued at $1,521,000 after buying an additional 9,497 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in shares of Progyny by 10.5% during the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 25,519 shares of the company's stock valued at $1,312,000 after buying an additional 2,433 shares during the last quarter. Institutional investors and hedge funds own 82.51% of the company's stock.About Progyny
(Get Rating)
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
Further Reading
- Get a free copy of the StockNews.com research report on Progyny (PGNY)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It's Cheap
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.